178 related articles for article (PubMed ID: 10898675)
1. Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects.
Weller S; Radomski KM; Lou Y; Stein DS
Antimicrob Agents Chemother; 2000 Aug; 44(8):2052-60. PubMed ID: 10898675
[TBL] [Abstract][Full Text] [Related]
2. Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults.
McDowell JA; Lou Y; Symonds WS; Stein DS
Antimicrob Agents Chemother; 2000 Aug; 44(8):2061-7. PubMed ID: 10898676
[TBL] [Abstract][Full Text] [Related]
3. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection.
Wang LH; Chittick GE; McDowell JA
Antimicrob Agents Chemother; 1999 Jul; 43(7):1708-15. PubMed ID: 10390227
[TBL] [Abstract][Full Text] [Related]
4. A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects.
Staszewski S; Katlama C; Harrer T; Massip P; Yeni P; Cutrell A; Tortell SM; Harrigan RP; Steel H; Lanier RE; Pearce G
AIDS; 1998 Nov; 12(16):F197-202. PubMed ID: 9833847
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral agents in infants and children with human immunodeficiency virus infection. AIDS Clinical Trials Group 330 Team.
Kline MW; Blanchard S; Fletcher CV; Shenep JL; McKinney RE; Brundage RC; Culnane M; Van Dyke RB; Dankner WM; Kovacs A; McDowell JA; Hetherington S
Pediatrics; 1999 Apr; 103(4):e47. PubMed ID: 10103339
[TBL] [Abstract][Full Text] [Related]
6. Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults.
Kumar PN; Sweet DE; McDowell JA; Symonds W; Lou Y; Hetherington S; LaFon S
Antimicrob Agents Chemother; 1999 Mar; 43(3):603-8. PubMed ID: 10049274
[TBL] [Abstract][Full Text] [Related]
7. Safety and single-dose pharmacokinetics of abacavir (1592U89) in human immunodeficiency virus type 1-infected children.
Hughes W; McDowell JA; Shenep J; Flynn P; Kline MW; Yogev R; Symonds W; Lou Y; Hetherington S
Antimicrob Agents Chemother; 1999 Mar; 43(3):609-15. PubMed ID: 10049275
[TBL] [Abstract][Full Text] [Related]
8. A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience.
Schooley RT; Clumeck N; Haubrich R; Thompson M; Danner SA; van Der Ende ME; Sereni D; Antunes F; Blake D; Myers RE; Tisdale M; Millard J; Mustafa N; Nacci P
Antivir Ther; 2001 Jun; 6(2):89-96. PubMed ID: 11491421
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team.
Sáez-Llorens X; Nelson RP; Emmanuel P; Wiznia A; Mitchell C; Church JA; Sleasman J; Van Dyke R; Richardson CG; Cutrell A; Spreen W; Hetherington S
Pediatrics; 2001 Jan; 107(1):E4. PubMed ID: 11134468
[TBL] [Abstract][Full Text] [Related]
10. Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects.
Moyle G; Boffito M; Fletcher C; Higgs C; Hay PE; Song IH; Lou Y; Yuen GJ; Min SS; Guerini EM
Antimicrob Agents Chemother; 2009 Apr; 53(4):1532-8. PubMed ID: 19188387
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.
Musiime V; Kendall L; Bakeera-Kitaka S; Snowden WB; Odongo F; Thomason M; Musoke P; Adkison K; Burger D; Mugyenyi P; Kekitiinwa A; Gibb DM; Walker AS;
Antivir Ther; 2010; 15(8):1115-24. PubMed ID: 21149918
[TBL] [Abstract][Full Text] [Related]
12. Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients.
Wood R; Arasteh K; Stellbrink HJ; Teofilo E; Raffi F; Pollard RB; Eron J; Yeo J; Millard J; Wire MB; Naderer OJ
Antimicrob Agents Chemother; 2004 Jan; 48(1):116-23. PubMed ID: 14693528
[TBL] [Abstract][Full Text] [Related]
13. Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team.
Saag MS; Sonnerborg A; Torres RA; Lancaster D; Gazzard BG; Schooley RT; Romero C; Kelleher D; Spreen W; LaFon S
AIDS; 1998 Nov; 12(16):F203-9. PubMed ID: 9833848
[TBL] [Abstract][Full Text] [Related]
14. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
Staszewski S; Keiser P; Montaner J; Raffi F; Gathe J; Brotas V; Hicks C; Hammer SM; Cooper D; Johnson M; Tortell S; Cutrell A; Thorborn D; Isaacs R; Hetherington S; Steel H; Spreen W;
JAMA; 2001 Mar; 285(9):1155-63. PubMed ID: 11231744
[TBL] [Abstract][Full Text] [Related]
15. The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study Team.
Katlama C; Clotet B; Plettenberg A; Jost J; Arasteh K; Bernasconi E; Jeantils V; Cutrell A; Stone C; Ait-Khaled M; Purdon S
AIDS; 2000 May; 14(7):781-9. PubMed ID: 10839585
[TBL] [Abstract][Full Text] [Related]
16. Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults.
McMahon D; Lederman M; Haas DW; Haubrich R; Stanford J; Cooney E; Horton J; Kelleher D; Ross L; Cutrell A; Lee D; Spreen W; Mellors JW
Antivir Ther; 2001 Jun; 6(2):105-14. PubMed ID: 11491415
[TBL] [Abstract][Full Text] [Related]
17. Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.
Ruane PJ; Parenti DM; Margolis DM; Shepp DH; Babinchak TJ; Van Kempen AS; Kauf TL; Danehower SA; Yau L; Hessenthaler SM; Goodwin D; Hernandez JE;
HIV Clin Trials; 2003; 4(4):231-43. PubMed ID: 12916008
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months.
Paediatric European Network for Treatment of AIDS (PENTA)
Antivir Ther; 2010; 15(3):297-305. PubMed ID: 20516550
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers.
Zhao W; Cella M; Della Pasqua O; Burger D; Jacqz-Aigrain E;
Br J Clin Pharmacol; 2012 Apr; 73(4):641-50. PubMed ID: 21988586
[TBL] [Abstract][Full Text] [Related]
20. Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of food.
Chittick GE; Gillotin C; McDowell JA; Lou Y; Edwards KD; Prince WT; Stein DS
Pharmacotherapy; 1999 Aug; 19(8):932-42. PubMed ID: 10453964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
